Find a Clinical Trial

Showing 151 - 160 of 171 Trials

  • Open-label, Single-Center, Phase 1 Study to Estimate the Minimum Effective Dose (MED) of 131I-apamistamab for non-myeloablative conditioning in Patients with Severe Sickle Cell Disease

    Principal Investigator:

    Markus Y Mapara, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT07015684

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to research the minimum effective dose (MED) of 131 I- apamistamab conditioning for hematopoietic stem cell transplantation for patients with advanced SCD. 131 Iapamistamab is an investigational product. This means that 131 I- apamistamab has not been approved by the Food and Drug Administration (FDA) for medical use in patients. The study treatment that is given before the transplant is called the conditioning regimen. In this study, we are adding a drug called 131 I-apamistamab instead of the conditioning regimen typically given before a stem cell transplant...

  • Phase 1b, Multicenter, Open-label, Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRASG12C-Mutated Solid Tumors

    Principal Investigator:

    Benjamin Herzberg, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06128551

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to test a combination of 2 new drugs called RMC-6291 and RMC 6236 (the study drugs). RMC-6291 and RMC-6236 are new investigational (ie, experimental) drugs, which means that they are not approved by the United States (US) Food and Drug Administration (FDA) or any other health authorities. This is the first study in which RMC 6291 and RMC-6236 will be tested together in humans. This study will test the safety and anti-tumor effects of RMC-6291 and RMC-6236 when given together at different doses in participants with a change or alteration in the KRASG12C gene within...

  • Phase 1, open label single-arm two-part study to investigate safety, pharmacokinetics, andpreliminary efficacy of pan-RAF/MEK glue NST-628 oral tablets in subjects with solid tumorsharboring genetic alterations in the MAPK pathway and with other solid

    Principal Investigator:

    Benjamin Herzberg, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06326411

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to find out if, and at what dose, NST-628 can safely treat solid cancers in patients who have no other treatment options left. NST-628 has been tested in animals and demonstrated some anti-tumor activity. This research study will be the first in which it will be given to humans and is experimental. “Experimental” means that the study drug has not been approved by any government authority responsible for the regulation of new medicines. This trial will explore what doses of NST-628 are safe and tolerable, as well as see whether NST-628 can slow the...

  • Phase 1 study of venetoclax/azacitidine or venetoclax in combination with ziftomenib (KO-539) or standard induction cytarabine/daunorubicin (7+3) chemotherapy in combination with ziftomenib for the treatment of patients with acute myeloid leukemia

    Principal Investigator:

    Joseph G. Jurcic, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05735184

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to determine the safe dose of ziftomenib to be used in combination with other drugs to treat acute myeloid leukemia. Another purpose is to determine how well ziftomenib works in combination with the other drugs for acute myeloid leukemia. Ziftomenib has not been approved by Food and Drug Administration (FDA). Ziftomenib is an experimental drug may help in preventing or slowing the leukemia cells from growing and dividing. Are you Eligible? (Inclusion Criteria) Must be 18 years old or older - Must have life expectancy greater than 3 months - Must not be diagnosis...

  • Phase I trial of ZEN003694 (ZEN-3694) in combination with capecitabine in patients with solid tumors

    Principal Investigator:

    Ryan H. Moy, MD, PhD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05803382

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to test the safety of a drug called ZEN003694 (ZEN-3694), in combination with the usual approach of capecitabine. This study tests different doses of ZEN003694 in combination with capecitabine to see which dose is safer for people. There will be between 21 and 30 people taking part in this study. This drug combination is not approved by the FDA for treatment of the disease being studied. Are you Eligible? (Inclusion Criteria) Are you 18 years of age or older? Have you been diagnosed with metastatic or unresectable cancer, which progressed while you were treated...

  • Phase I Study of Adoptive Immunotherapy of Refractory Viral Infection with ex vivo Expanded Rapidly Generated Virus Specific T (R-MVST) Cells

    Principal Investigator:

    Pawel Muranski, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05183490

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to test whether giving an experimental cell product can treat viral infection in patients who have conditions that cause the poor function of their immune system. The patients with infections caused by viruses such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), adenovirus (ADV), BK and JC polyomaviruses (PyVs) virus may participate in this study. The cell product is called rapidly generated virus-specific T cells (R-MVST). R-MVST cells will be manufactured in our laboratory at Columbia University Irving Medical Center. This cell product has not been approved...

  • Phase 1/Expansion Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma

    Principal Investigator:

    Jennifer Effie Amengual, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05627245

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to test the safety of drugs called tazemetostat and belinostat when administered together. This study tests different doses of the drugs to see which doses are safer for people. There will be between 21 and 48 people taking part in this study. There are two parts in this study, a dose escalation (dose finding) part and a dose expansion part (where the established dose is tested further). In the dose escalation part of this study, different people will get different doses of the study drugs tazemetostat and belinostat. The first 3 people taking part in this study...

  • R5458-ONC-2012:PHASE 1B STUDY OF REGN5458 (ANTI-BCMA X ANTICD3 BISPECIFIC ANTIBODY) PLUS OTHER CANCER TREATMENTS FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

    Principal Investigator:

    Rajshekhar Chakraborty, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05137054

    Population:

    Adult

    Phase:

    I
    This study is the first time REGN5458 will be combined with other cancer therapies. The main goal is to understand if REGN5458 can be given safely with other cancer study treatments, and if so, what dose of REGN5458 should be used for each combination. The investigational drug, REGN5458, is not approved by the Food and Drug Administration (FDA). Are you Eligible? (Inclusion Criteria) Are you at least 18 years of age? - Are you likely to live for at least six more months? -Do you have measurable disease as defined in the protocol according to International Myeloma Working Group (IMWG)...

  • Safety and Efficacy of Brodalumab in the Treatment of Immune-Related Adverse Events: A PilotStudy

    Principal Investigator:

    Brian Henick, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06673329

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to test the safety and effectiveness of using brodalumab in patients who develop side effects from cancer immune therapy. Immune-related side effects are due to activation of the immune system in patients who previously received immunotherapy and the goal of this study is to help better control these side effects. Brodalumab is often used to treat patients with autoimmune diseases (diseases where the immune system is activated against normal organs) and safe doses and treatment schedules have been determined in these patients. Immune-related side effects appear to...

  • DISRUPT: Aim 2

    Principal Investigator:

    Benjamin Herzberg, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05146297

    Population:

    Adult

    Phase:

    NA
    That Black, Indigenous, and People of Color (BIPOC) are more likely to die from their cancer is well known. Despite years of progress in cancer research and treatment, most research is done in white populations. For this reason, it is not certain how best to treat BIPOC with cancer. The number of people with cancer who join a clinical trial (CT) in the United States at 8%. This low number is due to many reasons including the things related to the healthcare system, the number and type of clinical trials that are available, and the other illnesses patients have. These factors affect BIPOC...

Pages